Organized by the Global Initiative for Asthma (GINA), World Asthma Day is an annual awareness day aimed at raising awareness of asthma and improving healthcare, with this year’s theme focusing on ‘Asthma care for All’1. Thanks to over 15 years of experience in FeNO monitoring, Bedfont® Scientific Ltd has developed a FeNO breath analysis device that can aid in the diagnosis and management of asthma. Bedfont® is working to increase access to FeNO monitoring worldwide through its dedicated network of distributors and Key Opinion Leaders.
Did you know that worldwide asthma affected an estimated 262 million people in 2019 and caused 455,000 deaths?2 The central process within asthma and many other lung diseases is airway inflammation, and being able to detect airway inflammation levels and monitor a patient’s response to treatment is regarded as a gold standard in the management of respiratory diseases.
When airways are inflamed Nitric Oxide (NO) is naturally produced by your body to help combat inflammation. This production of NO is often found to be higher in inflammatory conditions such as asthma, and an innovative way of detecting and managing such conditions is done through FeNO monitoring. Two funded projects in the UK have presented data from a staff survey in primary care that shows that 83% of survey respondents have felt that FeNO testing has improved confidence levels when diagnosing asthma, and 90% believe that access to FeNO testing has supported the diagnosis of asthma with patients3.
Fractional exhaled Nitric Oxide (FeNO) is a measure of the concentration of NO gas particles in exhaled breath, expressed in parts per billion (ppb). The NObreath® FeNO device by Bedfont® Scientific Ltd. is easy to use with its simple exhale-only technique and on-screen visual motivation. With over 10 years of clinical use featuring in many studies worldwide, the NObreath® FeNO device aids in the diagnosis & management of asthma for both adult and child patients, giving you the ability to also store up to 25 results in up to 50 patient profiles with full graph results.
With a handheld, portable, easy-to-use device, Bedfont® is helping to break FeNO accessibility barriers. Previously FeNO breath analysis has been expensive, however, we have made it more cost-effective by having low-cost mouthpieces with a long shelf-life. The NObreath® includes a 5-year warranty on the device and sensor, and we have also simplified the service and maintenance options. To find out how you can support your patients with FeNO monitoring to improve ‘Asthma care for All’ this World Asthma Day, visit https://www.nobreathfeno.com.
References:
1. Rurey K. 2023 World Asthma Day – Global Initiative for Asthma [Internet]. GINA. 2023 [cited 2023Apr4]. Available from: https://ginasthma.org/2023-world-asthma-day/
2. Asthma [Internet]. World Health Organization. World Health Organization; [cited 2023Apr17]. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma
3. Feno testing in Primary Care [Internet]. West of England Academic Health Science Network. 2023 [cited 2023Apr17]. Available from: https://www.weahsn.net/our-work/case-study/feno-testing-in-primary-care/